BRPI0417476A - derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer - Google Patents

derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer

Info

Publication number
BRPI0417476A
BRPI0417476A BRPI0417476-3A BRPI0417476A BRPI0417476A BR PI0417476 A BRPI0417476 A BR PI0417476A BR PI0417476 A BRPI0417476 A BR PI0417476A BR PI0417476 A BRPI0417476 A BR PI0417476A
Authority
BR
Brazil
Prior art keywords
disease
treatment
alzheimer
tricyclically
indole
Prior art date
Application number
BRPI0417476-3A
Other languages
English (en)
Inventor
Sally Redshaw
Emmanuel Hubert Demont
Daryl Simon Walter
David R Vesey
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0417476A publication Critical patent/BRPI0417476A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE INDOL HIDROXIETILAMINA TRICICLICA E SEU USO NO TRATAMENTO DA DOENçA DE ALZHEIMER A presente invenção se refere a novos compostos de hidroxietilamina com atividade inibidora de Asp2 ( - secretase, bacei ou memapsina) de fórmula (I), a processos para sua preparação, a composições que os contenham e a seu uso no tratamento de doenças caracterizadas por níveis de - amilóide elevados ou depósitos de -amilóide, particularmente doença de alzheimer. Na fórmula (I), entre outros, A-B representa -NR5-SO2- ou -NR5 -CO-; R5 representa hidrogênio,C1-6 alquila, C3-6 alcenila C3-6 alcinila, C3-10 cicloalquila, -C0-6 ALQUILARILA, -C0-6 alquil-heteroarila, -C0-6 alquil-heterociclila, -C3-10 cicloalquilarila ou -C3-10 CICLOALQUIL-HETEROARILA; -W- REPRESENTA -CH2-, -(CH2)2-, -(CH2)3-, -C(H) =C (H)- ou -CH2-C(H)=C(H)-; X-Y-Z representa -C=CR8-NR9 - .
BRPI0417476-3A 2003-12-12 2004-12-09 derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer BRPI0417476A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds
PCT/EP2004/014076 WO2005058915A1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BRPI0417476A true BRPI0417476A (pt) 2007-05-08

Family

ID=30130158

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417476-3A BRPI0417476A (pt) 2003-12-12 2004-12-09 derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer

Country Status (17)

Country Link
US (1) US20070073060A1 (pt)
EP (1) EP1692143B1 (pt)
JP (1) JP2007513913A (pt)
KR (1) KR20060121164A (pt)
CN (1) CN1914214A (pt)
AT (1) ATE414090T1 (pt)
AU (1) AU2004299231A1 (pt)
BR (1) BRPI0417476A (pt)
CA (1) CA2549072A1 (pt)
DE (1) DE602004017777D1 (pt)
GB (1) GB0328900D0 (pt)
IL (1) IL175819A0 (pt)
IS (1) IS8521A (pt)
MA (1) MA28241A1 (pt)
NO (1) NO20063137L (pt)
RU (1) RU2006124863A (pt)
WO (1) WO2005058915A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2573138A1 (en) 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1794115A2 (en) * 2004-09-21 2007-06-13 Pfizer Products Incorporated N-ethyl hydroxyethylamines useful in treating cns conditions
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
AU2008306835A1 (en) * 2007-07-27 2009-04-09 Sanofi-Aventis 1,2,3,4-tetrahydropyrrolo[1,2-A]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-A][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
JP6219955B2 (ja) * 2012-08-24 2017-10-25 トレヴェンティス コーポレイションＴｒｅｖｅｎｔｉｓ Ｃｏｒｐｏｒａｔｉｏｎ ベンゾフラザン抗アミロイド化合物および方法
US11214579B2 (en) * 2017-10-13 2022-01-04 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE287402T1 (de) * 1997-02-04 2005-02-15 Univ California Nanomolare, non-peptidische inhibitoren von cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
ES2248356T3 (es) * 2000-06-30 2006-03-16 Elan Pharmaceuticals, Inc. Compuestos para tratar la enfermedad de alzheimer.
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
ATE414090T1 (de) 2008-11-15
IS8521A (is) 2006-06-26
DE602004017777D1 (de) 2008-12-24
EP1692143B1 (en) 2008-11-12
RU2006124863A (ru) 2008-01-20
CN1914214A (zh) 2007-02-14
IL175819A0 (en) 2006-10-05
NO20063137L (no) 2006-08-31
WO2005058915A1 (en) 2005-06-30
EP1692143A1 (en) 2006-08-23
JP2007513913A (ja) 2007-05-31
MA28241A1 (fr) 2006-10-02
CA2549072A1 (en) 2005-06-30
US20070073060A1 (en) 2007-03-29
GB0328900D0 (en) 2004-01-14
KR20060121164A (ko) 2006-11-28
AU2004299231A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NO20063137L (no) Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
EP1912963A4 (en) CYCLIC KETALS AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.